Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated logoVertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VRTX
  • CUSIP: 92532F10
Key Metrics:
  • Previous Close: $90.04
  • 50 Day Moving Average: $89.50
  • 200 Day Moving Average: $85.02
  • 52-Week Range: $71.46 - $103.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 29.81
  • P/E Growth: 0.83
  • Market Cap: $22.24B
  • Outstanding Shares: 248,438,000
  • Beta: 0.79
Profitability:
  • Net Margins: -6.76%
  • Return on Equity: -2.15%
  • Return on Assets: -0.98%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 2.08%
  • Quick Ratio: 1.98%

Analyst Ratings

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (?)
Ratings Breakdown: 11 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.54)
Consensus Price Target: $101.73 (12.99% upside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/20/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
3/17/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$103.73 -> $115.00LowView Rating Details
3/14/2017ArgusReiterated RatingBuy$115.00 -> $92.95LowView Rating Details
3/7/2017BMO Capital MarketsReiterated RatingMarket Perform$78.00N/AView Rating Details
3/6/2017Robert W. BairdReiterated RatingOutperform$115.00N/AView Rating Details
3/1/2017Citigroup IncInitiated CoverageBuy -> Buy$105.00N/AView Rating Details
2/27/2017Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
2/11/2017Cowen and CompanySet Price TargetHold$75.00N/AView Rating Details
2/3/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
1/26/2017HC WainwrightSet Price TargetHold$85.00N/AView Rating Details
1/26/2017Stifel NicolausLower Price TargetBuy$108.00 -> $100.00N/AView Rating Details
1/20/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
1/8/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
1/3/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
12/25/2016Piper Jaffray CompaniesSet Price TargetBuy$129.00N/AView Rating Details
12/20/2016Credit Suisse Group AGSet Price TargetBuy$100.00N/AView Rating Details
12/7/2016Janney Montgomery ScottReiterated RatingNeutral$98.00N/AView Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$100.00 -> $90.00N/AView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
10/12/2016Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
9/13/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
7/28/2016Morgan StanleyLower Price TargetOverweight$140.00 -> $139.00N/AView Rating Details
4/28/2016Goldman Sachs Group IncDowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00N/AView Rating Details
3/15/2016Bank of America CorpReiterated RatingNeutral$108.00N/AView Rating Details
9/15/2015NomuraInitiated CoverageBuy$162.00N/AView Rating Details
7/31/2015Deutsche Bank AGReiterated RatingBuy$155.00N/AView Rating Details
7/7/2015BTIG ResearchLower Price TargetBuy$200.00 -> $180.00N/AView Rating Details
6/5/2015Canaccord GenuityReiterated RatingBuy$150.00N/AView Rating Details
(Data available from 3/23/2015 forward)

Earnings

Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017        
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Current Year EPS Consensus Estimate: $1.62 EPS
Next Year EPS Consensus Estimate: $3.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.09)($0.09)($0.09)
Q4 20163($0.07)$0.05$0.01
Q1 20172$0.03$0.03$0.03
Q2 20172$0.02$0.07$0.05
Q3 20171$0.09$0.09$0.09
Q4 20171$0.33$0.33$0.33
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 94.85%
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Source:
DateHeadline
News IconVertex Pharmaceuticals Incorporated (VRTX) Given "Outperform" Rating at Leerink Swann (NASDAQ:VRTX)
www.americanbankingnews.com - March 20 at 4:57 PM
News IconVertex Pharmaceuticals Incorporated (VRTX) Downgraded by Vetr Inc. to “Hold” (NASDAQ:VRTX)
www.americanbankingnews.com - March 19 at 7:01 PM
News IconVertex Pharmaceuticals Incorporated (VRTX) Raised to “Outperform” at JMP Securities (NASDAQ:VRTX)
www.americanbankingnews.com - March 18 at 2:03 AM
bizjournals.com logoInside the small Norwood biotech that's making investors swoon (NASDAQ:VRTX)
www.bizjournals.com - March 17 at 3:28 PM
finance.yahoo.com logoZacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals (NASDAQ:VRTX)
finance.yahoo.com - March 16 at 3:33 PM
News IconVertex Pharmaceuticals Incorporated (VRTX) Upgraded to Buy at Vetr Inc. (NASDAQ:VRTX)
www.americanbankingnews.com - March 15 at 12:24 AM
seekingalpha.com logoVertex's $160M Deal With Concert Pharmaceuticals (NASDAQ:VRTX)
seekingalpha.com - March 9 at 11:52 PM
biz.yahoo.com logoVERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements (NASDAQ:VRTX)
biz.yahoo.com - March 6 at 7:53 PM
fool.com logoThe Probable Reason Behind Vertex Pharmaceuticals 5% Jump in February (NASDAQ:VRTX)
us.rd.yahoo.com - March 6 at 11:42 AM
finance.yahoo.com logoVertex to Present at the Cowen Healthcare Conference on March 6 (NASDAQ:VRTX)
finance.yahoo.com - March 3 at 5:57 AM
us.rd.yahoo.com logoCoverage initiated on Vertex Pharma by Citigroup (NASDAQ:VRTX)
us.rd.yahoo.com - March 2 at 1:24 AM
bizjournals.com logoTrump gives Genzyme rare disease drug a shout-out in speech to Congress (NASDAQ:VRTX)
us.rd.yahoo.com - March 2 at 1:24 AM
us.rd.yahoo.com logoVERTEX PHARMACEUTICALS INC / MA Financials (NASDAQ:VRTX)
us.rd.yahoo.com - March 2 at 1:24 AM
finance.yahoo.com logoZacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte (NASDAQ:VRTX)
finance.yahoo.com - February 28 at 11:08 AM
nasdaq.com logoVRTX Makes Bullish Cross Above Critical Moving Average (NASDAQ:VRTX)
www.nasdaq.com - February 27 at 5:23 PM
us.rd.yahoo.com logoVertex Expects Modest Revenue Growth in This (NASDAQ:VRTX)
us.rd.yahoo.com - February 25 at 4:19 AM
seekingalpha.com logoVertex Pharmaceuticals Incorporated (VRTX) (NASDAQ:VRTX)
seekingalpha.com - February 23 at 11:45 PM
biz.yahoo.com logoVERTEX PHARMACEUTICALS INC / MA Files SEC form 10-K, Annual Report (NASDAQ:VRTX)
us.rd.yahoo.com - February 23 at 11:45 PM
bizjournals.com logoHeadcount at ​Vertex surges in 2016, hitting four-year high (NASDAQ:VRTX)
www.bizjournals.com - February 23 at 11:45 PM
nasdaq.com logoFirst Week of VRTX October 20th Options Trading (NASDAQ:VRTX)
www.nasdaq.com - February 22 at 11:11 AM
fool.com logoWhy Vertex Pharmaceuticals Stock Surged Higher in January (NASDAQ:VRTX)
www.fool.com - February 10 at 6:33 AM
finance.yahoo.com logoBlog Coverage Celgene Acquires Delinia; Set to Expand Inflammation and Immunology Portfolio (NASDAQ:VRTX)
finance.yahoo.com - January 27 at 3:49 PM
finance.yahoo.com logoBiotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals (NASDAQ:VRTX)
finance.yahoo.com - January 27 at 3:49 PM

Social

Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings results on Wednesday, January, 25th. The company reported $0.35 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.06. The company earned $458.71 million during the quarter, compared to the consensus estimate of $453.40 million. Vertex Pharmaceuticals Incorporated had a negative net margin of 6.76% and a negative return on equity of 2.15%. During the same period in the previous year, the business earned $0.17 earnings per share.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

24 analysts have issued 12-month target prices for Vertex Pharmaceuticals Incorporated's shares. Their predictions range from $75.00 to $139.00. On average, they expect Vertex Pharmaceuticals Incorporated's stock price to reach $101.73 in the next twelve months.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

  • 1. BMO Capital Markets analysts commented, "We believe Vertex's acquisition of Concert's CTP-656, a deuterated ivacaftor (Kalydeco), removes a key potential competitor in the cystic fibrosis space. In addition, CTP-656 could replace Kalydeco in the triple combo, allowing a once-daily (QD) regimen, which would offset an important advaVertex Pharma (NASDAQ: VRTX)ntage of Galapagos's QD triple combo in development. We also believe CTP-656's later patent expiration date (2032 vs. 2027 for Kalydeco) will be an important lifecycle management component of Vertex's cystic fibrosis franchise." (3/7/2017)
  • 2. Robert W. Baird analysts commented, "Vertex announced plans to acquire Concert Pharmaceuticals' CTP-656, or deuterated ivacaftor. We think this acquisition highlights Vertex's commitment to defending its position as the leading CF company as it both eliminates a potential competitor and allows access to a once-daily modified version of ivacaftor with a longer patent life than ivacaftor itself. Overall, we think this is a smart deal for the company at a reasonable price, and reiterate our Outperform rating." (3/6/2017)
  • 3. Cowen and Company analysts commented, "Last week we hosted meetings with Vertex management in Chicago." (2/11/2017)
  • 4. Maxim Group analysts commented, "The global launch of Orkambi in the homozygote CF population continues to make progress, and growth is expected as more European countries come online. However, as we move through 2017, our attention is turning towards expected data in the heterozygote population, where we believe Vertex must be successful to drive long-term value." (2/3/2017)
  • 5. According to Zacks Investment Research, "Vertex reported better-than-expected fourth-quarter 2016 results. Vertex has two cystic fibrosis (CF) drugs in its portfolio with blockbuster potential – Kalydeco & Orkambi. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase the patient population and boost sales. Vertex’s CF pipeline is also strong. However, we believe the 2017 Orkambi revenue guidance is below expectations and dependent on reimbursement discussions in Europe. Vertex expects that the upper end of the Orkambi sales guidance will be met only if it gets additional reimbursement and approvals in different European markets. Moreover, Vertex’s shares have consistently underperformed the Zacks categorized Biomed/Genetics industry in the past one year. Investor focus will now be on the triple combination CF regimens which are crucial for long-term growth at Vertex." (1/31/2017)

Are investors shorting Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated saw a drop in short interest during the month of February. As of February 28th, there was short interest totalling 5,537,864 shares, a drop of 17.3% from the February 15th total of 6,695,064 shares. Based on an average daily trading volume, of 1,556,596 shares, the short-interest ratio is presently 3.6 days.

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.09%), State Street Corp (4.74%), Orbimed Advisors LLC (0.87%), Norges Bank (0.70%), Franklin Resources Inc. (0.58%) and Fred Alger Management Inc. (0.55%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Margaret G Mcglynn, Paul M Silva, Stuart A Arbuckle, Terrence C Kearney and Yuchun Lee.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Thrivent Financial for Lutherans, Janus Capital Management LLC, I.G. Investment Management LTD., GLG LLC, Employees Retirement System of Texas and NN Investment Partners Holdings N.V.. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, Ian F Smith, Joshua S Boger, Paul M Silva and Stuart A Arbuckle.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Camber Capital Management LLC, Two Sigma Investments LP, Orbimed Advisors LLC, Baillie Gifford & Co., Asset Management One Co. Ltd., State Street Corp and AMF Pensionsforsakring AB.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vertex Pharmaceuticals Incorporated stock cost?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $90.04.

Vertex Pharmaceuticals Incorporated (VRTX) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by MarketBeat.com Staff